Arena rises on positive rat data outcome for weight loss drug lorcaserin
This article was originally published in Scrip
Executive Summary
Investors gave Arena Pharmaceuticals a 14% boost on 9 August on the positive outcome from the firm's pathology working group's (PWG) re-adjudication of female rat mammary tumour diagnoses from a two-year carcinogenicity study of the company's embattled experimental weight loss drug lorcaserin.